| Budget Amount *help |
¥24,830,000 (Direct Cost: ¥19,100,000、Indirect Cost: ¥5,730,000)
Fiscal Year 2014: ¥3,510,000 (Direct Cost: ¥2,700,000、Indirect Cost: ¥810,000)
Fiscal Year 2013: ¥6,110,000 (Direct Cost: ¥4,700,000、Indirect Cost: ¥1,410,000)
Fiscal Year 2012: ¥6,110,000 (Direct Cost: ¥4,700,000、Indirect Cost: ¥1,410,000)
Fiscal Year 2011: ¥9,100,000 (Direct Cost: ¥7,000,000、Indirect Cost: ¥2,100,000)
|
|---|
| Outline of Final Research Achievements |
Although induced pluripotent stem (iPS) cell-based cardiac regeneration therapy has been expected, safety, costs, and duration of iPS cell derivation are considered as barriers against the clinical application. To overcome these problems, we tried to modify the reprograming process, in order to create cardiac myocytes directly from fibroblasts rapidly and efficiently with few risks of tumorigenesis. Sca1+/CD34+ cells appeared in the early phase of four factor-mediated reprogramming of mouse embryonic fibroblasts. While these cells are not susceptible to iPS cell formation, they can be maintained during over 10 passages under a certain culture condition, and possess the ability to differentiate into cardiac myocytes. In addition, using bioluminescent imaging, these cells did not develop the teratoma formation after implantation into immune-deficient mice. Taken together, these cells could be a novel cell source for safe and efficient cardiac regeneration therapy.
|
